In overweight/obese patients without diabetes, taking GLP‐1 RAs could reduce the risk of MI by 27% (RR 0.73, 95% CI 0.55−0.96), but there was no significant change in the risk of stroke (RR 0.93, 95% CI 0.65−1.32). Here, GLP1R is linked to stroke disorder.